» Articles » PMID: 14744906

Supplemental Oxygen Improves Diabetic Macular Edema: a Pilot Study

Overview
Specialty Ophthalmology
Date 2004 Jan 28
PMID 14744906
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Diabetic macular edema (DME) is the most common cause of moderate visual disability in persons of working age in the United States. The pathogenesis of DME is poorly understood. In this study, the effect of retinal hypoxia in the development and maintenance of DME was investigated.

Methods: Five patients with chronic DME despite at least one focal laser photocoagulation treatment (nine eyes) received 4 L/min of inspired oxygen by nasal cannula for 3 months. Best corrected visual acuity (VA) and retinal thickness, assessed by optical coherence tomography (OCT), were measured at baseline, during 3 months of oxygen treatment, and for 3 months after stopping oxygen.

Results: After 3 months of oxygen therapy, nine of nine eyes with DME at baseline showed a reduction in thickness of the center of the macula. Foveal thickness (FTH) above the normal range was reduced by an average of 43.5% (range, 14%-100%), excess foveolar thickness (CEN) was reduced by an average of 42.1% (range, 13%-100%), and excess macular volume was reduced by an average of 54% (range, 35%-100%). Statistical analyses suggested that these changes were unlikely to be due to chance (P = 0.0077 by Wilcoxon signed-rank test). Three eyes showed improvement in VA by at least 2 lines, one by slightly less than 2 lines, and five eyes showed no change. Three months after discontinuation of oxygen, five of the nine eyes showed increased thickening of the macula compared with when oxygen was discontinued.

Conclusions: Supplemental inspired oxygen may decrease macular thickness due to DME, suggesting that retinal hypoxia is involved in the development and maintenance of DME.

Citing Articles

N-Acetylcysteine protects against cobalt chloride-induced endothelial dysfunction by enhancing glucose-6-phosphate dehydrogenase activity.

Yang C, Zhang X, Ge X, He C, Liu S, Yang S FEBS Open Bio. 2022; 12(8):1475-1488.

PMID: 35666067 PMC: 9340863. DOI: 10.1002/2211-5463.13449.


Diabetic macular ischaemia- a new therapeutic target?.

Cheung C, Fawzi A, Teo K, Fukuyama H, Sen S, Tsai W Prog Retin Eye Res. 2021; 89:101033.

PMID: 34902545 PMC: 11268431. DOI: 10.1016/j.preteyeres.2021.101033.


Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture.

Campochiaro P Invest Ophthalmol Vis Sci. 2021; 62(14):26.

PMID: 34817536 PMC: 8637787. DOI: 10.1167/iovs.62.14.26.


A Real-World Single-Centre Study of Patients with Diabetic Macular Oedema Who Wore a Home-Use Sleep Mask (Noctura 400) for One Year.

Meyer-Bothling U, Meyer-Bothling O, Pinney M J Ophthalmol. 2021; 2021:6612126.

PMID: 34258049 PMC: 8249224. DOI: 10.1155/2021/6612126.


Real-Time Monitoring the Effect of Cytopathic Hypoxia on Retinal Pigment Epithelial Barrier Functionality Using Electric Cell-Substrate Impedance Sensing (ECIS) Biosensor Technology.

Guerra M, Yumnamcha T, Ebrahim A, Berger E, Singh L, Ibrahim A Int J Mol Sci. 2021; 22(9).

PMID: 33925448 PMC: 8123793. DOI: 10.3390/ijms22094568.